Obesity Medicine in India: How GLP-1 Drugs (Mounjaro and Wegovy) Are Changing Everyday Practice

Obesity medicine in India is evolving rapidly as newer treatments change how doctors approach weight management and metabolic health. Medicines such as Mounjaro (tirzepatide) and Wegovy (semaglutide) have attracted significant attention from patients seeking medically supervised weight loss. For general physicians, family doctors and diabetologists, understanding these therapies is becoming an increasingly important clinical skill.

The growing use of obesity medicine in India and GLP-1 drugs also brings new responsibilities. Doctors must understand how these medications work, identify suitable patients, manage side effects and provide long-term follow-up. These treatments are not quick fixes; they are part of a broader medical weight-management plan that includes nutrition, physical activity, and behavioural support.

Why Obesity Is Now a Core Clinical Skill in India

Obesity is a chronic, complex condition associated with type 2 diabetes, hypertension, dyslipidaemia, cardiovascular disease, sleep apnoea and other metabolic complications. Effective management requires more than advising patients to eat less and exercise more.

The introduction of newer anti-obesity medication has expanded the treatment options available to eligible patients. Tirzepatide, marketed as Mounjaro, launched in India in March 2025, followed by semaglutide for obesity, marketed as Wegovy, in June 2025.

As awareness increases, patients are approaching physicians with questions about weight loss injections, treatment costs, safety and expected results. This creates an opportunity for an obesity clinic in India to offer structured, evidence-based care rather than medication without adequate assessment or follow-up.

Affordability is another important development. Following the March 2026 semaglutide patent expiry in India, additional products have entered the market. However, doctors should distinguish regulatory approval from actual availability and verify each formulation’s approved indication, quality and prescribing information.

For everyday clinical practice, the priority is to determine whether medication is appropriate for an individual patient and how it can be integrated into sustainable weight management.

How GLP-1 and Dual GIP/GLP-1 Agonists Work

GLP-1 stands for glucagon-like peptide-1, a hormone involved in appetite regulation and blood glucose control. GLP-1 receptor agonists mimic its activity and influence several processes that contribute to weight management.

These medicines work through multiple mechanisms:

• Appetite regulation: They act on pathways involved in hunger and satiety, helping patients feel satisfied with smaller meals.
• Reduced food intake: Changes in appetite and fullness can help patients consume fewer calories.
• Slower gastric emptying: Food may leave the stomach more slowly, particularly during the early stages of treatment.
• Glucose regulation: They enhance glucose-dependent insulin secretion and help regulate glucagon release.

Semaglutide is a GLP-1 receptor agonist. Tirzepatide, the active ingredient in Mounjaro, activates both GIP and GLP-1 receptors. This dual action influences appetite, energy intake and glucose metabolism.

Clinical studies have demonstrated meaningful weight loss in selected patients using these medicines alongside appropriate lifestyle interventions. However, results differ according to the medicine, dose, duration, adherence and individual health factors. Doctors should explain that clinical trial averages do not guarantee personal outcomes.

For physicians learning about GLP-1 agonists in India, understanding the difference between these medicines is essential. Their indications, approved formulations, dosing schedules and precautions are not automatically interchangeable.

Patient Selection and Realistic Expectations

Not every patient seeking weight loss needs medication. A proper assessment helps determine whether anti-obesity medication is appropriate, identifies relevant health risks and establishes realistic treatment goals.

Who May Qualify for Anti-Obesity Medication?

Indian clinical recommendations have supported considering pharmacotherapy at a BMI above 27 kg/m², or above 25 kg/m² when an associated comorbidity is present. The decision must also follow the specific medicine’s current Indian prescribing information and approved indication.

Before prescribing, assess:

• Weight, height, BMI and waist circumference.
• Previous weight-management attempts and the pattern of weight gain.
• Medical history, including diabetes, hypertension and cardiovascular risk factors.
• Relevant investigations, such as blood glucose or HbA1c and lipid profile.
• Current medicines, allergies and relevant gastrointestinal or endocrine history.
• Eating patterns, sleep, physical activity and readiness for continued follow-up.

Patients with type 2 diabetes may have additional reasons to consider these therapies. However, the choice of medicine should reflect the patient’s clinical needs and the approved use of the particular product.

Who Needs Additional Caution?

Pregnancy and plans for pregnancy require careful discussion because these medicines are not intended for weight loss during pregnancy. Clinicians should also evaluate relevant histories of pancreatitis, gallbladder disease and significant gastrointestinal motility problems.

Certain product labels include specific contraindications for people with a personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2. The exact precautions depend on the medicine and formulation, so current prescribing information must be checked.

Patients should also understand that stopping treatment can lead to weight regain. A long-term maintenance strategy is therefore an essential part of medical weight management.

Side Effects, Titration and Monitoring

Safe prescribing begins with informed counselling and continues throughout treatment. Patients should know what side effects to expect, when to contact their doctor and why they must not change doses independently.

Common Side Effects

Nausea, vomiting, diarrhoea, constipation, abdominal discomfort and reduced appetite are among the common adverse effects of GLP-1-based treatments. Symptoms may be more noticeable after treatment begins or the dose increases.

For mild symptoms, patients may benefit from eating smaller meals, eating slowly, avoiding unusually large or high-fat meals and maintaining adequate hydration.

More serious concerns include gallbladder complications, pancreatitis and severe gastrointestinal symptoms. Severe, persistent abdominal pain, repeated vomiting or signs of dehydration require prompt medical assessment.

Doctors should explain these warning signs before the first dose rather than waiting for a problem to occur.

How to Prescribe Semaglutide for Obesity

When considering how to prescribe semaglutide for obesity, clinicians should first confirm the indication, select the appropriate approved formulation and review contraindications.

Treatment generally begins at a low dose and increases gradually according to the product-specific schedule. This approach helps improve tolerability and allows the clinician to assess the patient’s response.

Essential prescribing principles include:

• Confirm the product, starting dose and administration schedule.
• Explain injection technique and storage requirements.
• Follow the approved titration schedule rather than increasing the dose prematurely.
• Reassess persistent adverse effects before further escalation.
• Avoid unsupervised dose changes or substitutions between formulations.

Semaglutide products intended for different indications may have different strengths and dosing schedules. Doctors should not assume that diabetes and obesity formulations are automatically interchangeable.

What Should Doctors Monitor?

Monitoring should extend beyond weight alone. Follow-up can include weight trends, waist circumference, blood pressure, adverse effects, hydration, dietary adequacy and relevant metabolic indicators.

For patients with diabetes, review glucose control and concurrent medications. Insulin and sulfonylureas may require particular attention because combining glucose-lowering therapies can increase hypoglycaemia risk.

Doctors should also discuss adequate nutrition and resistance exercise to help preserve muscle during weight loss. Treatment should be reassessed if side effects persist, the response is inadequate, or the patient’s clinical circumstances change.

Setting Up a Weight-Management Service in Your Clinic

A structured medical weight-management service can help physicians provide consistent care while improving patient understanding and follow-up.

1. Establish a Standard Assessment Protocol

Create a documented intake process covering anthropometric measurements, medical history, comorbidities, medication use, lifestyle factors and patient goals. Baseline measurements make it easier to evaluate progress objectively.

2. Develop an Individualised Treatment Plan

Discuss nutrition, physical activity, sleep, behavioural strategies and pharmacological options when indicated. Explain potential benefits, limitations, risks and costs before treatment begins.

3. Schedule Regular Follow-Up

Plan reviews during dose escalation and at clinically appropriate intervals thereafter. Assess treatment tolerance, adherence, weight trends and metabolic outcomes. Give patients clear instructions on when to contact the clinic.

4. Build a Multidisciplinary Network

Collaboration with dietitians, endocrinologists, mental health professionals and exercise or rehabilitation specialists can support patients with different needs. Complex cases may require specialist referral.

5. Maintain Ethical Prescribing Standards

Avoid presenting weight loss injections as cosmetic shortcuts or guaranteeing results. Use authorised medicines from regulated supply channels, document clinical decisions and ensure patients understand the need for ongoing care.

Will Cheaper Semaglutide Products Improve Access in India?

The March 2026 patent expiry has changed the commercial landscape for semaglutide in India, encouraging the entry of additional products. Increased competition may improve affordability, although actual prices and availability vary.

Doctors should verify the regulatory status and approved indication of each product instead of assuming all semaglutide formulations are identical. Patients should avoid unverified online sellers and products of uncertain origin.

As access expands, clinical judgement and patient education will remain essential. Lower prices do not remove the need for appropriate prescribing, monitoring and follow-up.

Frequently Asked Questions

Are GLP-1 weight-loss drugs safe?

They can be appropriate for eligible patients when prescribed and monitored by a qualified clinician. Gastrointestinal side effects are common, and serious complications can occur. Individual risk assessment and product-specific precautions are essential.

Who is eligible for anti-obesity medication?

Eligibility depends on BMI, weight-related complications, medical history and the medicine’s approved indication. A physician should assess each patient before recommending treatment.

How do GLP-1 drugs work for weight loss?

They influence appetite and satiety, helping reduce food intake. They also affect glucose regulation, while delayed gastric emptying contributes to some treatment effects and gastrointestinal side effects.

Is Mounjaro safe for Indian patients?

Tirzepatide may be suitable for eligible patients when prescribed according to its approved indication and product information. Safety depends on individual medical history, concurrent medicines, contraindications and ongoing clinical supervision.

How do I monitor patients on GLP-1 therapy?

Review weight trends, side effects, hydration, nutritional adequacy, blood pressure and relevant metabolic indicators. For patients with diabetes, review glucose control and concurrent medicines, particularly insulin and sulfonylureas.

Will cheaper semaglutide products be available in India?

Additional semaglutide products have entered the Indian market following the patent expiry in 2026. Availability, price, approved indications, and product characteristics should be verified using current regulatory information.

Conclusion

Mounjaro, Wegovy and other semaglutide formulations are expanding the role of obesity medicine in India. For general physicians, safe treatment depends on appropriate patient selection, evidence-based prescribing, gradual titration, side-effect counselling and long-term follow-up.

As medical weight management becomes more accessible, clinicians need a strong foundation in metabolic health and chronic disease care. Structured professional education can help doctors build this knowledge and apply it responsibly in everyday practice.

Explore the Fellowship in Diabetology, Certificate in Diabetology, Fellowship in Endocrinology and Certificate in Endocrinology programmes to learn more about relevant educational pathways for doctors.